Robert V. Cerwinski

Mr. Cerwinski’s recent work includes representing:

• Celltrion in BPCIA litigation concerning Celltrion’s biosimilar to Herceptin. Genentech v Celltrion (D. Del.)
• Celltrion in BPCIA litigation concerning Celltrion’s biosimilar to Rituxan. Genentech v Celltrion (D.N.J.)
• Actavis in Hatch-Waxman patent infringement litigation concerning Actavis’s generic equivalent to Noxafil®, an antibiotic. A favorable settlement was obtained after trial. Merck v. Fresenius (D. Del.)
• Dr. Reddy’s in Hatch-Waxman patent infringement litigation concerning DRL’s generic equivalent to Suboxone®, an anti-addiction product. A judgment of non-infringement was obtained after trial. Indivior v. DRL (D. Del.)
• Fresenius in Hatch-Waxman patent infringement litigation concerning Fresenius’s generic equivalent to Cubicin®, an antibiotic. A favorable settlement was obtained before trial. Cubist v. Fresenius (D. Del.)
• Actavis in Hatch-Waxman patent infringement litigation concerning Actavis’s generic equivalent to Staxyn®, an ED medication. A judgment of patent invalidity was obtained after an appeal to the Federal Circuit. Bayer v. Actavis (D. Del.)
• Teva in Hatch-Waxman patent infringement litigation concerning Teva's generic equivalent to Pfizer's Atelvia®, an osteoporosis medication. Warner Chilcott v. Teva Pharmaceuticals (D.N.J.)
• Teva in Hatch-Waxman patent infringement litigation concerning Teva's generic equivalent to Pfizer's Neurontin®, an epilepsy medication. A favorable settlement was obtained during jury trial. Warner-Lambert v. Teva Pharmaceuticals (D.N.J.)
• Teva in Hatch-Waxman litigation concerning Teva's generic equivalent to OxyContin®, an opioid pain medication. A favorable settlement was obtained prior to trial. Purdue Pharma v. Teva Pharmaceuticals (S.D.N.Y.)
• Teva in a patent infringement action concerning Teva's generic equivalent to Biaxin®, an antibiotic. A favorable settlement was obtained while summary judgment motion was pending. Abbott Laboratories v. Teva Pharmaceuticals (N.D. Ill.)
• Teva in patent infringement action concerning Teva's generic equivalent to Biaxin XL®, an antibiotic. A favorable settlement was obtained after the Federal Circuit vacated a preliminary injunction. Abbott Laboratories v. Teva Pharmaceuticals (N.D. Ill.)
• Teva in a patent infringement action concerning Teva's generic equivalent to Augmentin®, an antibiotic. Seven patents were invalidated in two summary judgment motions and a bench trial. Teva Pharmaceuticals v. GlaxoSmithKline (E.D. Va.)
• Teva in a patent infringement action involving Teva's equivalent to Wellbutrin®, an antidepressant. A favorable settlement was obtained. Glaxo Wellcome v. Teva Pharmaceuticals (D. Del.)
• Teva in Hatch-Waxman litigation concerning Teva's equivalent to Zithromax®, an antibiotic. A favorable settlement was obtained while summary judgment motions were pending. Teva Pharmaceuticals v. Pfizer (S.D.N.Y.)
• Breckenridge in a patent infringement action involving Breckenridge's sulfatol acne medication. A favorable settlement was obtained. Bradley Pharmaceuticals v. Breckenridge Pharmaceutical (D.N.J.)
• Teva in Hatch-Waxman litigation concerning generic equivalents to Allegra® and Allegra-D 12 Hour® allergy medications. The case settled after a preliminary injunction was denied and summary judgments of non-infringement and invalidity were obtained. Aventis and AMR v. Teva Pharmaceuticals (D.N.J.)
• Estée Lauder in a patent infringement litigation concerning cosmetic emulsions. A favorable settlement was obtained. Revlon v. Estée Lauder (S.D.N.Y.)
• Faulding in patent infringement litigation concerning Cardizem CD®, a hypertension medication. A favorable settlement was obtained. Hoechst Marion Roussel v. Faulding (D.N.J.)
• American Home Products and Takeda Chemical Industries in a patent infringement litigation concerning acellular pertussis vaccines. Summary judgment of non-infringement was obtained. Evans Medical v. American Cyanamid (S.D.N.Y.)